Abstract:Despite the decline in their proliferative potential, senescent cells display a high metabolic activity. Senescent cells have been shown to acquire a more glycolytic state even in presence of high oxygen levels, in a way similar to cancer cells. The diversion of pyruvate, the final product of glycolysis, away from oxidative phosphorylation results in an altered bioenergetic state and may occur as a response to the enhanced oxidative stress caused by the accumulation of dysfunctional mitochondria. This metabolic shift leads to increased AMP/ATP and ADP/ATP ratios, to the subsequent AMPK activation, and ultimately to p53-mediated growth arrest. Mounting evidences suggest that metabolic reprogramming is critical to direct considerable amounts of energy toward specific activities related to the senescent state, including the senescence-associated secretory phenotype (SASP) and the modulation of immune responses within senescent cell tissue microenvironment. Interestingly, despite the relative abundance of oxygen in the vascular compartment, healthy endothelial cells (ECs) produce most of their ATP content from the anaerobic conversion of glucose to lactate. Their high glycolytic rate further increases during senescence. Alterations in EC metabolism have been identified in age-related diseases (ARDs) associated with a dysfunctional vasculature, including atherosclerosis, type 2 diabetes and cardiovascular diseases. In particular, higher production of reactive oxygen species deriving from a variety of enzymatic sources, including uncoupled endothelial nitric oxide synthase and the electron transport chain, causes DNA damage and activates the NAD+-consuming enzymes polyADP-ribose polymerase 1 (PARP1). These non-physiological mechanisms drive the impairment of the glycolytic flux and the diversion of glycolytic intermediates into many pathological pathways. Of note, accumulation of senescent ECs has been reported in the context of ARDs. Through their pro-oxidant, pro-inflammatory, vasoconstrictor, and prothrombotic activities, they negatively impact on vascular physiology, promoting both the onset and development of ARDs. Here, we review the current knowledge on the cellular senescence-related metabolic changes and their contribution to the mechanisms underlying the pathogenesis of ARDs, with a particular focus on ECs. Moreover, current and potential interventions aimed at modulating EC metabolism, in order to prevent or delay ARD onset, will be discussed.

A homoeostatic switch causing glycerol-3-phosphate and phosphoethanolamine accumulation triggers senescence by rewiring lipid metabolism

Senescent glia link mitochondrial dysfunction and lipid accumulation

Oxidative Glucose Metabolism Promotes Senescence in Vascular Endothelial Cells

p53 enables phospholipid headgroup scavenging

Lipids and Lipid Metabolism in Cellular Senescence: Emerging Targets for Age-Related Diseases

P53-dependent hypusination of eIF5A affects mitochondrial translation and senescence immune surveillance

Disrupted Binding of Cystathionine γ-Lyase to p53 Promotes Endothelial Senescence

Lipid remodeling in context of cellular senescence

Phosphoglycerate dehydrogenase activates PKM2 to phosphorylate histone H3T11 and attenuate cellular senescence

Decreased autophagy and fuel switching occur in a senescent hepatic cell model system

Lipid and glucose metabolism in senescence

Targeting cellular senescence in metabolic disease

Inactivation of Lsd1 triggers senescence in trophoblast stem cells by induction of Sirt4

Targeting senescent cells alleviates obesity-induced metabolic dysfunction

Mitochondria-to-nucleus retrograde signaling drives formation of cytoplasmic chromatin and inflammation in senescence

Where Metabolism Meets Senescence: Focus on Endothelial Cells

Towards a Rosetta Stone to Decipher the Survival Networks of Senescence

Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging

The induction of the fibroblast extracellular senescence metabolome is a dynamic process

Persistent mTORC1 signaling in cell senescence results from defects in amino acid and growth factor sensing

Senescent cells promote tissue NAD+ decline during ageing via the activation of CD38+ macrophages